Latest news with #IntegralDiagnostics
Yahoo
26-05-2025
- Business
- Yahoo
Shareholders in Integral Diagnostics (ASX:IDX) are in the red if they invested five years ago
Ideally, your overall portfolio should beat the market average. But even the best stock picker will only win with some selections. At this point some shareholders may be questioning their investment in Integral Diagnostics Limited (ASX:IDX), since the last five years saw the share price fall 34%. The falls have accelerated recently, with the share price down 16% in the last three months. So let's have a look and see if the longer term performance of the company has been in line with the underlying business' progress. We've discovered 3 warning signs about Integral Diagnostics. View them for free. While markets are a powerful pricing mechanism, share prices reflect investor sentiment, not just underlying business performance. By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time. Integral Diagnostics became profitable within the last five years. Most would consider that to be a good thing, so it's counter-intuitive to see the share price declining. Other metrics may better explain the share price move. In contrast to the share price, revenue has actually increased by 13% a year in the five year period. So it seems one might have to take closer look at the fundamentals to understand why the share price languishes. After all, there may be an opportunity. You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values). It's probably worth noting we've seen significant insider buying in the last quarter, which we consider a positive. That said, we think earnings and revenue growth trends are even more important factors to consider. This free report showing analyst forecasts should help you form a view on Integral Diagnostics It is important to consider the total shareholder return, as well as the share price return, for any given stock. The TSR is a return calculation that accounts for the value of cash dividends (assuming that any dividend received was reinvested) and the calculated value of any discounted capital raisings and spin-offs. So for companies that pay a generous dividend, the TSR is often a lot higher than the share price return. In the case of Integral Diagnostics, it has a TSR of -25% for the last 5 years. That exceeds its share price return that we previously mentioned. And there's no prize for guessing that the dividend payments largely explain the divergence! Integral Diagnostics shareholders gained a total return of 1.2% during the year. Unfortunately this falls short of the market return. But at least that's still a gain! Over five years the TSR has been a reduction of 5% per year, over five years. It could well be that the business is stabilizing. It's always interesting to track share price performance over the longer term. But to understand Integral Diagnostics better, we need to consider many other factors. Take risks, for example - Integral Diagnostics has 3 warning signs (and 2 which are significant) we think you should know about. Integral Diagnostics is not the only stock insiders are buying. So take a peek at this free list of small cap companies at attractive valuations which insiders have been buying. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Australian exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
06-04-2025
- Business
- Yahoo
April 2025's Top Undervalued Small Caps With Insider Action In The Asian Market
Amid heightened global trade tensions and economic uncertainty, Asian markets have been significantly impacted by the recent U.S. tariff announcements, with small-cap stocks facing particular challenges as evidenced by declines in key indices. In this environment, identifying promising small-cap opportunities requires a keen focus on companies with strong fundamentals and strategic insider action that could signal potential resilience or growth despite broader market volatility. Name PE PS Discount to Fair Value Value Rating Security Bank 4.8x 1.1x 38.24% ★★★★★★ New Hope 5.3x 1.5x 37.86% ★★★★★★ Atturra 26.2x 1.1x 42.82% ★★★★★☆ Puregold Price Club 8.6x 0.4x 12.39% ★★★★☆☆ Dicker Data 18.6x 0.6x -31.97% ★★★★☆☆ Sing Investments & Finance 7.4x 3.7x 41.75% ★★★★☆☆ PWR Holdings 34.7x 4.8x 24.71% ★★★☆☆☆ Zip Co NA 1.8x -29.36% ★★★☆☆☆ Integral Diagnostics 149.7x 1.7x 43.99% ★★★☆☆☆ Manawa Energy NA 2.6x 43.39% ★★★☆☆☆ Click here to see the full list of 59 stocks from our Undervalued Asian Small Caps With Insider Buying screener. Let's explore several standout options from the results in the screener. Simply Wall St Value Rating: ★★★☆☆☆ Overview: Integral Diagnostics operates diagnostic imaging facilities and has a market capitalization of approximately A$1.15 billion. Operations: The company generates revenue primarily from operating diagnostic imaging facilities, with the latest reported revenue at A$491.32 million. Over recent periods, the gross profit margin has shown a slight decline to 31.66%. Operating expenses and non-operating expenses have been significant factors affecting net income, which recently turned positive after several quarters of losses. PE: 149.7x Integral Diagnostics, with a market value of A$837 million, is attracting attention from private equity firms after recent share price declines. Despite this, insider confidence is evident as an individual purchased 36,000 shares for A$78,840 in early 2025. The company reported half-year sales of A$252.87 million and a net loss reduction to A$0.396 million from the previous year's A$66.76 million loss. Earnings are projected to grow by 40% annually, indicating potential future growth despite current challenges in covering interest payments through earnings alone. Take a closer look at Integral Diagnostics' potential here in our valuation report. Review our historical performance report to gain insights into Integral Diagnostics''s past performance. Simply Wall St Value Rating: ★★★☆☆☆ Overview: PWR Holdings specializes in the design and manufacturing of advanced cooling solutions for the automotive and motorsports industries, with a market capitalization of A$1.16 billion. Operations: The company's primary revenue streams are from PWR C&R and PWR Performance Products, with total revenues reaching A$138.074 million in the latest period. The gross profit margin has fluctuated over time, with a recent figure of 79.69%. Operating expenses have increased to A$82.945 million, impacting net income which stands at A$19.108 million for the same period. PE: 34.7x PWR Holdings, a smaller player in Asia, shows potential despite recent challenges. The company reported A$62.9 million in sales for the half year ending December 31, 2024, down from A$64.22 million the previous year, with net income also dropping to A$4.08 million from A$9.78 million. Insider confidence is evident as they purchased shares recently, suggesting belief in future growth prospects despite current earnings pressure and a reduced dividend of A$0.02 per share announced for March 2025. Click here and access our complete valuation analysis report to understand the dynamics of PWR Holdings. Gain insights into PWR Holdings' past trends and performance with our Past report. Simply Wall St Value Rating: ★★★☆☆☆ Overview: Far East Orchard is involved in property investment and hospitality operations, focusing on property ownership and management services, with a market capitalization of approximately SGD 0.61 billion. Operations: The company's revenue streams are primarily derived from hospitality operations and property ownership, with significant contributions from student accommodation and management services. Over recent periods, the gross profit margin has shown a notable increase, reaching 49.60% by the end of 2024. PE: 8.5x Far East Orchard, a small-cap stock in Asia, presents an intriguing opportunity due to its current valuation. Recent insider confidence is evident from share purchases in the past year, signaling potential growth prospects. The company announced a special dividend of 1 Singapore cent per share and a final dividend of 4 cents for FY2024 after divesting RHPC. Despite its reliance on external borrowing for funding, it maintains high-quality earnings with minimal one-off impacts. Unlock comprehensive insights into our analysis of Far East Orchard stock in this valuation report. Explore historical data to track Far East Orchard's performance over time in our Past section. Click here to access our complete index of 59 Undervalued Asian Small Caps With Insider Buying. Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks. Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ASX:IDX ASX:PWH and SGX:O10. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Yahoo
01-04-2025
- Business
- Yahoo
3 ASX Stocks Estimated To Be Up To 42.8% Below Intrinsic Value
Amidst recent market fluctuations, with Australian shares poised for a potential bounceback following one of the toughest trading days of 2025, investors are eyeing opportunities on the ASX. In such volatile times, identifying stocks that are perceived to be undervalued can be particularly appealing, offering potential value against current market conditions. Name Current Price Fair Value (Est) Discount (Est) Acrow (ASX:ACF) A$1.09 A$2.01 45.8% Nido Education (ASX:NDO) A$0.795 A$1.57 49.3% Nick Scali (ASX:NCK) A$15.69 A$27.51 43% Environmental Group (ASX:EGL) A$0.245 A$0.46 46.9% PolyNovo (ASX:PNV) A$1.165 A$2.12 44.9% Charter Hall Group (ASX:CHC) A$16.78 A$31.89 47.4% Genetic Signatures (ASX:GSS) A$0.475 A$0.88 45.8% SciDev (ASX:SDV) A$0.445 A$0.82 45.5% ReadyTech Holdings (ASX:RDY) A$2.60 A$5.13 49.3% Polymetals Resources (ASX:POL) A$0.87 A$1.69 48.6% Click here to see the full list of 40 stocks from our Undervalued ASX Stocks Based On Cash Flows screener. Below we spotlight a couple of our favorites from our exclusive screener. Overview: Integral Diagnostics Limited is a healthcare services company that provides diagnostic imaging services to medical professionals and patients in Australia and New Zealand, with a market cap of A$843.54 million. Operations: Revenue for Integral Diagnostics is primarily generated from the operation of diagnostic imaging facilities, amounting to A$491.32 million. Estimated Discount To Fair Value: 42.8% Integral Diagnostics (IDX) is trading at A$2.27, significantly below its estimated fair value of A$3.97, suggesting it may be undervalued based on cash flows. Despite a recent net loss of A$0.396 million for H1 2025, IDX's earnings are expected to grow substantially over the next three years at 40.2% per year, outpacing the Australian market's growth rate of 11.8%. However, interest payments are not well covered by earnings and private equity interest remains high following a drop in market value to A$837 million after recent results. Insights from our recent growth report point to a promising forecast for Integral Diagnostics' business outlook. Click to explore a detailed breakdown of our findings in Integral Diagnostics' balance sheet health report. Overview: James Hardie Industries plc manufactures and sells fiber cement, fiber gypsum, and cement bonded building products for construction applications across the United States, Australia, Europe, New Zealand, and the Philippines with a market cap of A$15.89 billion. Operations: The company's revenue segments are comprised of North America Fiber Cement at $2.88 billion, Asia Pacific Fiber Cement at $543.30 million, and Europe Building Products at $488 million. Estimated Discount To Fair Value: 34.4% James Hardie Industries, trading at A$36.98, is substantially below its estimated fair value of A$56.41, highlighting potential undervaluation based on cash flows. The company's earnings are projected to grow annually by 18.1%, outpacing the Australian market's 11.8% growth rate. Recent acquisition plans with The AZEK Company Inc., alongside a strategic partnership with David Weekley Homes, could enhance long-term growth prospects despite recent stable earnings performance and slight revenue decline year-over-year. Our growth report here indicates James Hardie Industries may be poised for an improving outlook. Click here to discover the nuances of James Hardie Industries with our detailed financial health report. Overview: Select Harvests Limited is an Australian company involved in the cultivation, processing, packaging, and sale of almonds and its by-products, with a market cap of A$724.75 million. Operations: The company's revenue is primarily derived from its almond segment, which generated A$337.29 million. Estimated Discount To Fair Value: 18.3% Select Harvests, trading at A$5.1, is undervalued compared to its fair value estimate of A$6.24 and offers significant earnings growth potential with a forecasted 34.3% annual increase, surpassing the Australian market's 11.8%. Despite recent shareholder dilution and large one-off items affecting earnings quality, revenue is expected to grow faster than the market at 9% annually. Recent executive changes include appointing Liam Nolan as CFO and Mark Rhys Davies as Joint Company Secretaries. The analysis detailed in our Select Harvests growth report hints at robust future financial performance. Navigate through the intricacies of Select Harvests with our comprehensive financial health report here. Discover the full array of 40 Undervalued ASX Stocks Based On Cash Flows right here. Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive. Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ASX:IDX ASX:JHX and ASX:SHV. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Yahoo
27-03-2025
- Business
- Yahoo
Integral Diagnostics Limited's (ASX:IDX) top owners are retail investors with 50% stake, while 44% is held by institutions
Integral Diagnostics' significant retail investors ownership suggests that the key decisions are influenced by shareholders from the larger public A total of 25 investors have a majority stake in the company with 47% ownership Insiders have been buying lately The end of cancer? These 15 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's. A look at the shareholders of Integral Diagnostics Limited (ASX:IDX) can tell us which group is most powerful. We can see that retail investors own the lion's share in the company with 50% ownership. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn). Institutions, on the other hand, account for 44% of the company's stockholders. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease their ownership over time. Let's take a closer look to see what the different types of shareholders can tell us about Integral Diagnostics. See our latest analysis for Integral Diagnostics Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing. As you can see, institutional investors have a fair amount of stake in Integral Diagnostics. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Integral Diagnostics, (below). Of course, keep in mind that there are other factors to consider, too. We note that hedge funds don't have a meaningful investment in Integral Diagnostics. Our data shows that Challenger Limited is the largest shareholder with 5.4% of shares outstanding. In comparison, the second and third largest shareholders hold about 5.0% and 4.5% of the stock. On studying our ownership data, we found that 25 of the top shareholders collectively own less than 50% of the share register, implying that no single individual has a majority interest. While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too. The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO. I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions. Our most recent data indicates that insiders own less than 1% of Integral Diagnostics Limited. But they may have an indirect interest through a corporate structure that we haven't picked up on. It seems the board members have no more than AU$7.0m worth of shares in the AU$858m company. Many tend to prefer to see a board with bigger shareholdings. A good next step might be to take a look at this free summary of insider buying and selling. With a 50% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Integral Diagnostics. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run. We can see that Private Companies own 4.5%, of the shares on issue. It's hard to draw any conclusions from this fact alone, so its worth looking into who owns those private companies. Sometimes insiders or other related parties have an interest in shares in a public company through a separate private company. It's always worth thinking about the different groups who own shares in a company. But to understand Integral Diagnostics better, we need to consider many other factors. Consider for instance, the ever-present spectre of investment risk. We've identified 3 warning signs with Integral Diagnostics (at least 2 which are potentially serious) , and understanding them should be part of your investment process. Ultimately the future is most important. You can access this free report on analyst forecasts for the company. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
07-03-2025
- Business
- Yahoo
Insider Actions Highlight 3 Undervalued Small Caps In Global Market
In the current global market landscape, small-cap stocks are navigating a challenging environment characterized by declining consumer confidence and persistent inflation concerns, as seen in recent economic indicators. While major indices like the S&P 600 have faced pressure, this environment can often highlight opportunities for discerning investors who focus on companies with strong fundamentals and strategic insider actions. Name PE PS Discount to Fair Value Value Rating Bytes Technology Group 19.5x 5.0x 23.27% ★★★★★★ Macfarlane Group 10.4x 0.6x 40.95% ★★★★★★ Speedy Hire NA 0.2x 26.26% ★★★★★☆ Hong Leong Asia 9.4x 0.2x 43.95% ★★★★☆☆ 4imprint Group 16.4x 1.3x 34.70% ★★★★☆☆ Gamma Communications 22.6x 2.3x 35.57% ★★★★☆☆ Franchise Brands 38.0x 2.0x 27.04% ★★★★☆☆ Optima Health NA 1.5x 44.96% ★★★★☆☆ Calfrac Well Services 11.3x 0.2x -28.93% ★★★☆☆☆ Saturn Oil & Gas 1.7x 0.5x -43.80% ★★★☆☆☆ Click here to see the full list of 116 stocks from our Undervalued Global Small Caps With Insider Buying screener. Let's uncover some gems from our specialized screener. Simply Wall St Value Rating: ★★★☆☆☆ Overview: Integral Diagnostics operates diagnostic imaging facilities, providing medical imaging services across Australia and New Zealand, with a market cap of A$741.29 million. Operations: Revenue is primarily generated from diagnostic imaging facilities, with the latest reported revenue at A$491.32 million. The gross profit margin has shown a declining trend, reaching 31.66% in the most recent period. Operating expenses and non-operating expenses have significantly impacted net income, which was recorded at A$5.66 million recently after a period of negative net income figures. PE: 150.3x Integral Diagnostics, a smaller company in the healthcare sector, recently reported half-year sales of A$252.87 million, up from A$231.25 million the previous year. Despite this growth, they faced a net loss of A$0.396 million compared to a larger loss previously. Insider confidence is evident with recent insider purchases over the last few months. However, financial challenges remain as interest payments aren't fully covered by earnings and funding relies on external borrowing sources only. Click here and access our complete valuation analysis report to understand the dynamics of Integral Diagnostics. Assess Integral Diagnostics' past performance with our detailed historical performance reports. Simply Wall St Value Rating: ★★★☆☆☆ Overview: Pantoro is a gold exploration and production company primarily focused on its Norseman Gold Project, with a market capitalization of A$0.13 billion. Operations: Pantoro's revenue primarily comes from the Norseman Gold Project, with recent figures showing a gross profit margin of -22.16%. The company has faced challenges in managing its cost of goods sold (COGS), which exceeded its revenue, resulting in negative gross profits. Operating expenses have fluctuated over time, impacting the overall financial performance. PE: -18.3x Pantoro, a mining company, has caught attention for its potential in the undervalued stock category. Recent insider confidence is evident with share purchases over the past year. The appointment of Stuart Mathews as an Independent Non-Executive Director on January 22, 2025, adds strategic depth due to his extensive experience in mine development and operations. Despite relying on external borrowing for funding, earnings are projected to grow by 51% annually. This positions Pantoro well for future growth opportunities in the gold sector. Get an in-depth perspective on Pantoro's performance by reading our valuation report here. Review our historical performance report to gain insights into Pantoro's's past performance. Simply Wall St Value Rating: ★★☆☆☆☆ Overview: Manawa Energy is a company focused on generating and providing electricity, with a market capitalization of NZ$1.87 billion. Operations: The company primarily generates revenue from electricity generation and provision, with recent figures showing revenue of NZ$561.11 million. The gross profit margin has shown variability, reaching 50.60% in September 2023 but declining to 34.99% by September 2024. Operating expenses have consistently included significant amounts for general and administrative costs, which were NZ$34.27 million as of the latest period reported in September 2024. PE: -42.8x Manawa Energy, a small energy player, has caught attention with insider confidence as insiders have been purchasing shares consistently over the past year. Despite being heavily reliant on external borrowing for funding, which presents higher risk without customer deposits to balance it out, the company is positioned well financially. Earnings are projected to grow at 45% annually. This growth potential could signal opportunities in the energy sector despite its current undervalued status in the market. Click to explore a detailed breakdown of our findings in Manawa Energy's valuation report. Learn about Manawa Energy's historical performance. Navigate through the entire inventory of 116 Undervalued Global Small Caps With Insider Buying here. Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports. Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ASX:IDX ASX:PNR and NZSE:MNW. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
